

Blue Cross Blue Shield of Texas

Diagnostic testing of iron homeostasis and metabolism



Policy Number: CPCPLAB008 Version 1.0

Approval Date: February 5, 2025

Plan Effective Date: May 15, 2025

CPT® codes: 82728, 83540, 83550, 84466, 84999, 0024U, 0251U

Condition or Test	May Be Reimbursable in the Following Situations	Is Not Reimbursable in the Following Situations
Serum Ferritin Testing	Measurement of serum ferritin levels may be reimbursable in any of the following situations listed in the 8 rows below.	For all other situations not addressed in the middle columns, measurement of ferritin or transferrin levels, including transferrin saturation, is not reimbursable
Abnormal Hemoglobin or Hematocrit	For the evaluation of an individual with abnormal hemoglobin and/or hematocrit levels	—
Iron Overload Disorders	For the evaluation and monitoring of iron overload disorders	—
Symptoms of Hemochromatosis	For individuals with symptoms of hemochromatosis (see Note 1 below for symptoms list). For the evaluation of iron overload in individuals with symptoms of hemochromatosis (See Note 1 below for symptoms list)	—
First-Degree Relatives with Hereditary Hemochromatosis	For individuals with first-degree relatives (See Note 2 below for definition of first-degree relatives) with confirmed hereditary hemochromatosis (HH)	—
Liver Disease	For the evaluation of individuals with liver disease	—
HLH and Still Disease	For the evaluation of hemophagocytic lymphohistiocytosis (HLH) and Still Disease	—
Secondary Hypogonadism in Males	In males with secondary hypogonadism	—
Chronic Kidney Disease or Iron Therapy	At a frequency of every 1 to 3 months: For the evaluation and monitoring of patients with chronic kidney disease who are receiving or being considered for receiving treatment for anemia; For individuals on iron therapy	—
Transferrin Saturation	Measurement of serum transferrin saturation may be reimbursable in the situation listed below:	—
Iron Deficiency Anemia	For the evaluation of iron deficiency anemia	—
Serum Hcpidin Testing	—	Serum hepcidin testing, including immunoassays, is not reimbursable
GlycA Testing	—	The use of GlycA testing to measure or monitor transferrin or other glycosylated proteins is not reimbursable

Note 1: Symptoms of hemochromatosis, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health include the following (NIDDK, 2020): Joint pain , Fatigue, Unexplained weight loss, Abnormal bronze or gray skin color, Abdominal pain, Loss of sex drive

Note 2: First-degree relatives include parents, full siblings, and children of the individual.

To view the complete policy, please refer to the Blue Cross Blue Shield of Texas policy document referenced below: <https://www.bcbstx.com/docs/provider/tx/standards/clinical-pay-coding/lab-mgmt/cpcplab008-dx-test-iron-metabolism-02052025.pdf>

Disclaimer: This associated condition reference guide is provided as an aid to physicians and office staff in determining when testing is medically necessary. The diagnosis must be applicable to the patient's symptoms or conditions and must be consistent with documentation in the patient's medical record. Quest Diagnostics does not recommend any diagnosis codes or conditions and will only submit diagnosis information provided to us by the ordering physician or his/her designated staff. The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

QuestDiagnostics.com Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—®, and ™ —are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. 3/2026